2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatients
2024
Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer
Kim S, Kim S, Kim E, Cecchini M, Park M, Choi J, Kim S, Hwang H, Kang C, Choi H, Shin S, Kang J, Lee C. Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer. JCO Clinical Cancer Informatics 2024, 8: e2400021. PMID: 39151114, DOI: 10.1200/cci.24.00021.Peer-Reviewed Original ResearchConceptsArea under the receiver operating characteristic curveSurvival of patientsCT reportsPancreatic cancerNatural language processingC-indexPredicting survivalOverall survival of patientsTertiary hospitalPredicting 1-year survivalPredicting survival of patientsImproved C-indexSurvival informationPancreatic cancer survivalReceiver operating characteristic curveInternal test data setNLP modelsComputed tomography reportsLanguage processingKorean tertiary hospitalOverall survivalConsecutive patientsActual survivalConcordance indexPatients
2019
Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals
Tan W, Berg S, Cole A, Krimphove M, Marchese M, Lipsitz S, Nabi J, Sammon J, Choueiri T, Kibel A, Sun M, Chang S, Trinh Q. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectrum 2019, 3: pkz003. PMID: 31360891, PMCID: PMC6649692, DOI: 10.1093/jncics/pkz003.Peer-Reviewed Original ResearchLow-stage renal cell carcinomaRenal cell carcinomaTreated with radical nephrectomyInverse probability of treatment weighting adjustmentPartial nephrectomyRadical nephrectomyType of surgeryOverall survivalTreatment weighting adjustmentCell carcinomaClinical stageCompare overall survival of patientsPatients treated with partial nephrectomyLong-term overall survivalCT1 renal cell carcinomaOverall survival of patientsCox proportional hazards regression analysisProportional hazards regression analysisCompare overall survivalNational Cancer DatabaseMedian follow-upSurvival of patientsKaplan-Meier curvesInverse probabilityLong-term outcomes
2016
PCN33 Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting
Oh W, Miao R, Duh, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Fortier J, Dhawan R. PCN33 Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting. Value In Health 2016, 19: a139. DOI: 10.1016/j.jval.2016.03.1655.Peer-Reviewed Original ResearchMicrosatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Koi M, Garcia M, Choi C, Kim H, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen Y, Mukherjee B, Boland C, Carethers J. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016, 150: 944-955. PMID: 26752111, PMCID: PMC4808397, DOI: 10.1053/j.gastro.2015.12.032.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorChi-Square DistributionChromosome AberrationsChromosomes, Human, Pair 9Colorectal NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansJapanKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Republic of KoreaRisk FactorsTime FactorsTreatment OutcomeConceptsPrimary colorectal tumorsLoss of heterozygosityLiver metastasesColorectal cancerColorectal tumorsElevated microsatellite alterationsMicrosatellite alterationsStage IICurative treatment of patientsStage III colorectal cancerOverall survival of patientsSurvival of patientsIII colorectal cancerTumor to liverColorectal cancer recurrenceTreatment of patientsMatched liver metastasesCancer cell nucleiMatched metastasesDisease recurrenceOverall survivalPrognostic factorsAllelic lossNo significant differenceCurative treatment
2012
Does a common vascular origin confer similar prognosis to malignant tumors of the liver?
Groeschl R, Pappas S, Christians K, Tsai S, Quebbeman E, Gamblin T, Turaga K. Does a common vascular origin confer similar prognosis to malignant tumors of the liver? Journal Of Clinical Oncology 2012, 30: 186-186. DOI: 10.1200/jco.2012.30.4_suppl.186.Peer-Reviewed Original ResearchMalignant vascular tumorsEpithelioid variantHepatic malignant vascular tumorsOverall survival of patientsAbsence of surgical interventionAnnual standardized incidenceSurvival of patientsAssociated with survivalCox regression modelsStandardized incidence rateMedian survivalSurgical resectionTumor histologyOverall survivalDistant metastasisPrognostic factorsSEER databaseVascular tumorsHepatic hemangiomaShorter survivalSurgical interventionHepatic angiosarcomaMalignant tumorsMetastatic potentialAngiosarcoma
1997
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V, Klimstra D, Venkatraman E, Pisters P, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clinical Cancer Research 1997, 3: 515-22. PMID: 9815714.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDisease ProgressionErbB ReceptorsGene Expression Regulation, NeoplasticHumansImmunohistochemistryLigandsLung NeoplasmsNeoplasm StagingPredictive Value of TestsSurvival RateTime FactorsTransforming Growth Factor alphaConceptsNon-small cell lung cancerOverexpression of epidermal growth factor receptorEpidermal growth factor receptorResected non-small cell lung cancerTGF-alpha overexpressionCell lung cancerTGF-alphaGrowth factor receptorOverall survivalTumor stageStimulatory loopTumor progressionEarly-stage non-small cell lung cancerLung cancerFactor receptorTumor formationOverall survival of patientsExpression of epidermal growth factorLigand transforming growth factor-alphaGrowth factorAutocrine growth stimulatory loopSquamous cell carcinomaSurvival of patientsLog-rank testLung tumor formation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply